Arena Subscribes to Celera Discovery System to Help Identify GPCRs | GenomeWeb

NEW YORK, March 15 – Arena Pharmaceuticals has enlisted the help of Celera’s databases and bioinformatics tools to identify G protein-coupled receptors (GPCRs), the companies said Thursday. 

Financial terms of Arena's multi-year subscription to the Celera Discovery System were not disclosed, but Celera has previously said that non-academic subcribers pay $5 million to $15 million a year. After signing Arena, Celera now has eight known commercial subscribers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."